Live: Will Aehr Test Systems Crush Tonight’s Q4 Earnings After the Market Closes?

Health and Healthcare

Biogen : BIIB

All Biogen Articles

607 Articles

Chris Lange | Sep 11, 2014 at 9:20 AM EDT

Short Sellers Remain Vigilant Against Biotechs

Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the latest…

Lee Jackson | Sep 8, 2014 at 8:35 AM EDT

Credit Suisse Releases New Top Investment Ideas

With less than one-third of the year remaining, many portfolio managers are looking for some outperformance so they can catch…

Chris Lange | Aug 27, 2014 at 10:25 AM EDT

Rising Short Interest in Biotech Stocks

Short sellers might be inclined to bet against biotech companies because of their volatile behavior on the charts.

Lee Jackson | Aug 20, 2014 at 8:40 AM EDT

6 Biotech Stocks to Buy Now With Up to 100% Upside Potential

ThinkstockWith the biotech space having its usual volatile ups and downs this year, the analysts at Stifel have stepped back…

Jon C. Ogg | Jul 29, 2014 at 8:40 AM EDT

Top Analyst Upgrades and Downgrades: AcelRx, Alcoa, Costco, Lululemon, Walmart, Trulia and More

These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Tuesday, July 29, 2014. They include…

Jon C. Ogg | Jul 20, 2014 at 9:11 AM EDT

Top Biotech Earnings Previews for the Week Ahead

ThinkstockEarnings season is now well under way for the second quarter. So far, things are looking good. The biotech sector…

Jon C. Ogg | Jun 19, 2014 at 2:05 PM EDT

Will Celgene Trigger Other Biotech Stock Splits?

Celgene has decided to join the stock split game. Even though stock splits change nothing fundamentally, 24/7 Wall St. would…

Jon C. Ogg | Jun 11, 2014 at 6:50 AM EDT

Short Sellers Remain Vigilant Against Top Biotech Stocks

ThinkstockShort sellers have many reasons to bet against a stock, some of which are hedging or part of a larger…

Trey Thoelcke | Jun 9, 2014 at 9:25 AM EDT

Large Cap Biotech Stocks to Buy Leading the Comeback Rally

A new research note from Credit Suisse maintains that the top large cap biotech leaders are leading the comeback rally…

Paul Ausick | Jun 7, 2014 at 9:40 AM EDT

Icahn Takes Stake in Family Dollar

ThinkstockActivist investor Carl Icahn filed documents with the Security and Exchange Commission (SEC) late Friday announcing that he had acquired…

Trey Thoelcke | Jun 3, 2014 at 8:45 AM EDT

Top Biotech Stocks to Buy According to Portfolio Managers

A new research report from Cowen suggests that biotech investors appear to be looking forward to what they describe as…

Jon C. Ogg | Jun 2, 2014 at 8:55 AM EDT

Analyst Cancer and Biotech Stock Picks From ASCO

ThinkstockAs the summer starts, a large agenda is out there for investors when it comes to top biotech and specialty…

Jon C. Ogg | May 29, 2014 at 7:55 AM EDT

Top Analyst Upgrades and Downgrades: AngloGold, Twitter, Biogen, Celgene, HomeAway, VMware and More

These are the top Wall Street analyst upgrades, downgrades and initiations for Thursday, May 29, 2014. They include AngloGold Ashanti,…

Jon C. Ogg | May 8, 2014 at 8:35 AM EDT

RBC Doctor Panel Picks in Drugs and Biotech

In a new research report, the pharmaceutical and biotech analysts at RBC highlight their meetings with a group of six…

Jon C. Ogg | Apr 30, 2014 at 10:55 AM EDT

The Next Big Stock Splits After Apple

In a new research report, analysts at Credit Suisse wonder if Apple's huge seven-for-one split may start a new trend.…

1 … 26 27 28 29 30 … 41

Biogen : BIIB

All Biogen Articles

Short Sellers Remain Vigilant Against Biotechs

Credit Suisse Releases New Top Investment Ideas

Rising Short Interest in Biotech Stocks

6 Biotech Stocks to Buy Now With Up to 100% Upside Potential

Top Analyst Upgrades and Downgrades: AcelRx, Alcoa, Costco, Lululemon, Walmart, Trulia and More

Top Biotech Earnings Previews for the Week Ahead

Will Celgene Trigger Other Biotech Stock Splits?

Short Sellers Remain Vigilant Against Top Biotech Stocks

Large Cap Biotech Stocks to Buy Leading the Comeback Rally

Icahn Takes Stake in Family Dollar

Top Biotech Stocks to Buy According to Portfolio Managers

Analyst Cancer and Biotech Stock Picks From ASCO

Top Analyst Upgrades and Downgrades: AngloGold, Twitter, Biogen, Celgene, HomeAway, VMware and More

RBC Doctor Panel Picks in Drugs and Biotech

The Next Big Stock Splits After Apple

Live: Will Aehr Test Systems Crush Tonight’s Q4 Earnings After the Market Closes?

She Claimed Social Security at 62 and Regretted It Within the Year. One Form Let Her Take It All Back

You Saved for 40 Years. 48% of Retirees Have No Plan for Spending It. Here’s What a Plan Looks Like.

The Fidelity Bond ETF Quietly Outperforming Vanguard’s BND Over The Last Decade

She Claimed Social Security at 62 and Regretted It Within the Year. One Form Let Her Take It All Back

You Saved for 40 Years. 48% of Retirees Have No Plan for Spending It. Here's What a Plan Looks Like.

She Claimed Social Security at 62 and Regretted It Within the Year. One Form Let Her Take It All Back

You Saved for 40 Years. 48% of Retirees Have No Plan for Spending It. Here’s What a Plan Looks Like.

Biogen : BIIB

All Biogen Articles

Short Sellers Remain Vigilant Against Biotechs

Credit Suisse Releases New Top Investment Ideas

Rising Short Interest in Biotech Stocks

6 Biotech Stocks to Buy Now With Up to 100% Upside Potential

Top Analyst Upgrades and Downgrades: AcelRx, Alcoa, Costco, Lululemon, Walmart, Trulia and More

Top Biotech Earnings Previews for the Week Ahead

Will Celgene Trigger Other Biotech Stock Splits?

Short Sellers Remain Vigilant Against Top Biotech Stocks

Large Cap Biotech Stocks to Buy Leading the Comeback Rally

Icahn Takes Stake in Family Dollar

Top Biotech Stocks to Buy According to Portfolio Managers

Analyst Cancer and Biotech Stock Picks From ASCO

Top Analyst Upgrades and Downgrades: AngloGold, Twitter, Biogen, Celgene, HomeAway, VMware and More

RBC Doctor Panel Picks in Drugs and Biotech

The Next Big Stock Splits After Apple

Live: Will Aehr Test Systems Crush Tonight’s Q4 Earnings After the Market Closes?

She Claimed Social Security at 62 and Regretted It Within the Year. One Form Let Her Take It All Back

You Saved for 40 Years. 48% of Retirees Have No Plan for Spending It. Here’s What a Plan Looks Like.

The Fidelity Bond ETF Quietly Outperforming Vanguard’s BND Over The Last Decade

Featured Reads

She Claimed Social Security at 62 and Regretted It Within the Year. One Form Let Her Take It All Back

You Saved for 40 Years. 48% of Retirees Have No Plan for Spending It. Here's What a Plan Looks Like.